ESTRING RING (SLOW-RELEASE)

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

ESTRADIOL

থেকে পাওয়া:

PFIZER CANADA ULC

এটিসি কোড:

G03CA03

INN (আন্তর্জাতিক নাম):

ESTRADIOL

ডোজ:

2MG

ফার্মাসিউটিকাল ফর্ম:

RING (SLOW-RELEASE)

রচনা:

ESTRADIOL 2MG

প্রশাসন রুট:

VAGINAL

প্যাকেজ ইউনিট:

1

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ESTROGENS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0106457001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2001-04-11

পণ্য বৈশিষ্ট্য

_ _
_ESTRING*(17 β-Estradiol) Product Monograph _
_Page 1 of 38 _
PRODUCT MONOGRAPH
PR
ESTRING *
(
17 Β-ESTRADIOL
)
_ _
Vaginal Ring, 2 mg
_ _
_ _
ESTROGEN
Pfizer Canada Inc.
Date of Revision:
17,300 Trans-Canada Highway
November 16, 2017
Kirkland, Quebec H9J 2M5
CONTROL NUMBER: 208652
*TM Pfizer Health AB
Pfizer Canada Inc., Licensee
© Pfizer Canada Inc. 2017
Distributed by: Paladin Labs Inc.
St-Laurent, Quebec, H4M 2P2
_ _
_ESTRING*(17 β-Estradiol) Product Monograph _
_Page 2 of 38 _
TABLE OF CONTENTS
PART 1: HEALTH PROFESSIONAL INFORMATION
.............................................................................................
3
SUMMARY
PRODUCT
INFORMATION
................................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
...........................................................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................................................
15
DRUG
INTERACTIONS
...........................................................................................................................................
19
DOSAGE
AND
ADMINISTRATION
.......................................................................................................................
21
OVERDOSAGE
..........................................................................................................................................................
22
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................................................
22
STORAGE
AND
STABI